A wave of new drugs have revolutionised the weight loss industry. Now, getting your hands on one popular medication could get ...

This report covers recent developments in the health sector, including proposed US federal budget cuts affecting scientific ...

We recently published a list of These 10 Firms Soared Last Week, Here’s Why. In this article, we are going to take a look at ...

Novo Nordisk's GLP-1 receptor agonist semaglutide ... which is already seeing sales rocket on the back of its use as Ozempic for diabetes, Wegovy for obesity, and label extensions for both brands ...

Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure therapy in mid-stage ...

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...